CalciMedica Inc., a clinical-stage biopharmaceutical company, has announced the publication of a manuscript in the American Journal of Nephrology regarding the design and rationale of the Phase 2 KOURAGE trial of their lead candidate, Auxora™. This trial targets acute kidney injury (AKI) with respiratory failure. The publication includes preclinical data from AKI models and a post-hoc analysis from the Phase 2 CARDEA trial involving patients with severe COVID-19 pneumonia and AKI. Results from these studies indicated a significant increase in glomerular filtration rate and reduced mortality in Auxora-treated subjects. The KOURAGE trial will focus on patients with AKI and respiratory failure, with the primary endpoint being the number of days patients are alive without requiring a ventilator or dialysis.